BG
LPCN icon

BlackRock Group’s Lipocine LPCN Stock Holding History

BlackRock Group’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-3,649
Closed -$630K – 3033
2016
Q1 		$630K Buy
+3,649
New +$623K ﹤0.01% 2139

Other funds holding LPCN

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock Group's LPCN Position: Q2 2016 in Review

BlackRock Group sold out of Lipocine (LPCN) in Q2 2016, closing a stake of 3,649 shares — an estimated $630K sold.

BlackRock Group first reported a position in LPCN in Q1 2016 and held it in 1 quarter. The position peaked at $630K in Q1 2016. 54 funds tracked by Wall St. Rank hold LPCN as of Q2 2016.

  • BlackRock Group reported no remaining Lipocine position as of Q2 2016 after selling out during the quarter.
  • BlackRock Group sold 3,649 Lipocine shares in Q2 2016, an estimated $630K.
  • BlackRock Group first reported a position in Lipocine in Q1 2016 and held it in 1 quarter.
  • BlackRock Group's Lipocine position peaked at $630K in Q1 2016.
  • 54 funds tracked by Wall St. Rank held Lipocine as of Q2 2016.

Based on BlackRock Group's 13F filing for Q2 2016, filed 10 Aug 2016.